Barry J. Simon - 20 Feb 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Director
Signature
/s/ Philip LoScalzo, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
20 Feb 2026
Net transactions value
-$1,836,028
Form type
4
Filing time
24 Feb 2026, 20:03:46 UTC
Previous filing
21 Jan 2026
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Simon Barry J. Director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO /s/ Philip LoScalzo, as Attorney-in-Fact 24 Feb 2026 0001647994

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Sale $92,500 -10,000 -0.32% $9.25 3,081,604 20 Feb 2026 Direct F1
transaction IBRX Common Stock Options Exercise $0 +15,243 +0.49% $0.000000 3,096,847 22 Feb 2026 Direct F2
transaction IBRX Common Stock Tax liability $52,426 -6,026 -0.19% $8.70 3,090,821 22 Feb 2026 Direct F3
transaction IBRX Common Stock Sale $1,691,102 -165,000 -5.3% $10.25 2,925,821 23 Feb 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -15,243 -50% $0.000000 15,245 22 Feb 2026 Common Stock 15,243 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
F3 On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
F4 Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.